JP2020502135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502135A5 JP2020502135A5 JP2019531812A JP2019531812A JP2020502135A5 JP 2020502135 A5 JP2020502135 A5 JP 2020502135A5 JP 2019531812 A JP2019531812 A JP 2019531812A JP 2019531812 A JP2019531812 A JP 2019531812A JP 2020502135 A5 JP2020502135 A5 JP 2020502135A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- plasminogen
- composition according
- drug
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016110174 | 2016-12-15 | ||
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| CNPCT/CN2016/110169 | 2016-12-15 | ||
| CN2016110169 | 2016-12-15 | ||
| PCT/CN2017/089059 WO2018107699A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗药物性肾损伤的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502135A JP2020502135A (ja) | 2020-01-23 |
| JP2020502135A5 true JP2020502135A5 (https=) | 2020-07-30 |
| JP7242057B2 JP7242057B2 (ja) | 2023-03-20 |
Family
ID=62557856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531812A Active JP7242057B2 (ja) | 2016-12-15 | 2017-06-19 | 薬物性腎損傷を予防及び治療するための方法 |
| JP2019531809A Active JP7182793B2 (ja) | 2016-12-15 | 2017-06-19 | 病理学的腎組織損傷を予防及び治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531809A Active JP7182793B2 (ja) | 2016-12-15 | 2017-06-19 | 病理学的腎組織損傷を予防及び治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190328848A1 (https=) |
| EP (2) | EP3556388A4 (https=) |
| JP (2) | JP7242057B2 (https=) |
| CN (2) | CN110366427A (https=) |
| CA (2) | CA3047171A1 (https=) |
| TW (4) | TW202123962A (https=) |
| WO (3) | WO2018107699A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7213552B2 (ja) | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| TWI868051B (zh) | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CN113456579B (zh) * | 2021-07-12 | 2023-04-25 | 南开大学 | 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| CN87104683A (zh) * | 1986-05-15 | 1988-12-21 | 埃默里大学 | 改善血纤维蛋白溶解作用的组合物 |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| MXPA04007585A (es) * | 2002-02-06 | 2005-09-20 | N Zyme Biotec Gmbh | Metodo para la produccion de proteinas recombinantes en microorganismos. |
| JP2006507297A (ja) * | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| CA2509170A1 (en) * | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| US20050250694A1 (en) | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| AU2005277137A1 (en) * | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as PAI-1 inhibitors |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| US8318661B2 (en) * | 2006-08-28 | 2012-11-27 | Omnio Healer Ab | Candidates against infection |
| JP5736597B2 (ja) * | 2009-05-26 | 2015-06-17 | ウニベルシダド・デ・サラマンカ | 急性腎不全又は急性腎不全発症リスクのマーカーとしての尿中ｇｍ２活性化タンパク質 |
| KR20120050442A (ko) * | 2009-07-10 | 2012-05-18 | 쓰롬보제닉스 엔.브이. | 플라스미노겐 및 플라스민의 변이체 |
| CN102121023B (zh) * | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| EP2661493B1 (en) * | 2011-01-05 | 2016-03-30 | ThromboGenics N.V. | Plasminogen and plasmin variants |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| CN106913860A (zh) | 2011-09-29 | 2017-07-04 | 梅约医学教育与研究基金会 | 芳族阳离子肽和使用它们的方法 |
| HK1221725A1 (zh) * | 2013-08-13 | 2017-06-09 | Sanofi | 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 |
| PL3109320T3 (pl) * | 2014-02-21 | 2019-08-30 | Astellas Pharma Inc. | Nowe przeciwciało anty-ludzki PAI-1 |
-
2017
- 2017-06-19 JP JP2019531812A patent/JP7242057B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089059 patent/WO2018107699A1/zh not_active Ceased
- 2017-06-19 TW TW110102361A patent/TW202123962A/zh unknown
- 2017-06-19 TW TW106120455A patent/TW201822797A/zh unknown
- 2017-06-19 CA CA3047171A patent/CA3047171A1/en not_active Abandoned
- 2017-06-19 EP EP17881449.7A patent/EP3556388A4/en active Pending
- 2017-06-19 US US16/469,960 patent/US20190328848A1/en not_active Abandoned
- 2017-06-19 CN CN201780078167.1A patent/CN110366427A/zh active Pending
- 2017-06-19 JP JP2019531809A patent/JP7182793B2/ja active Active
- 2017-06-19 EP EP17880935.6A patent/EP3556386A4/en active Pending
- 2017-06-19 WO PCT/CN2017/089055 patent/WO2018107695A1/zh not_active Ceased
- 2017-06-19 US US16/469,991 patent/US20190343930A1/en not_active Abandoned
- 2017-06-19 WO PCT/CN2017/089060 patent/WO2018107700A1/zh not_active Ceased
- 2017-06-19 CN CN201780078117.3A patent/CN110167582A/zh active Pending
- 2017-06-19 CA CA3047170A patent/CA3047170A1/en not_active Abandoned
- 2017-06-20 TW TW106120523A patent/TWI661838B/zh active
- 2017-06-20 TW TW106120521A patent/TWI642441B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502135A5 (https=) | ||
| Yu et al. | Expert consensus on the use of human serum albumin in critically ill patients | |
| Banerjee et al. | Management of heart failure patient with CKD | |
| Priante et al. | Cell death in the kidney | |
| Finkel et al. | THE CLINICAL APPLICATION OF CRRT—CURRENT STATUS: Complications of Continuous Renal Replacement Therapy | |
| Rabe et al. | Non-transgenic mouse models of kidney disease | |
| Chiurchiu et al. | Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses | |
| Rodríguez‐Romo et al. | Epigenetic regulation in the acute kidney injury to chronic kidney disease transition | |
| JP2020511416A5 (https=) | ||
| Dell’anna et al. | Early neuroprotection after cardiac arrest | |
| JP2020502155A5 (https=) | ||
| Iqbal et al. | Diuretic resistance and its management | |
| JP2020502134A5 (https=) | ||
| Ponticelli et al. | Renin-angiotensin system inhibitors in kidney transplantation: a benefit-risk assessment | |
| Baldwin et al. | Treatment of hypertension in renal disease | |
| CN110167582A (zh) | 一种预防和治疗药物性肾损伤的方法 | |
| Kaldre et al. | Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids | |
| Bassand | Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis | |
| Palmer et al. | Renal considerations in the treatment of hypertension | |
| Nieto-Ríos et al. | Nephrotic syndrome as a manifestation of thrombotic microangiopathy due to long-term use of sunitinib | |
| Anderson | Antihypertensive therapy in experimental diabetes. | |
| Singh et al. | Effects of Salacia oblonga on cardiovascular risk factors in chronic kidney disease patients: a prospective study | |
| Ogawa et al. | Urgent statement on antithrombotic therapy of atrial fibrillation | |
| Sever et al. | CD2AP, dendrin, and cathepsin L in the kidney | |
| Rosner et al. | Drug-associated acute kidney injury in the intensive care unit |